Commonwealth Equity Services Inc Acquires New Position in Myriad Genetics, Inc. (MYGN)
Commonwealth Equity Services Inc acquired a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,610 shares of the company’s stock, valued at approximately $202,000.
Other large investors also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. boosted its position in shares of Myriad Genetics by 1,067.4% during the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after buying an additional 3,010 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Myriad Genetics during the 2nd quarter valued at about $101,000. Riverhead Capital Management LLC lifted its position in shares of Myriad Genetics by 80.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after buying an additional 1,861 shares in the last quarter. Fiduciary Trust Co. purchased a new position in shares of Myriad Genetics during the 2nd quarter valued at about $113,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Myriad Genetics during the 3rd quarter valued at about $204,000.
Shares of Myriad Genetics, Inc. (NASDAQ MYGN) opened at $32.88 on Wednesday. The stock has a market capitalization of $2,321.64, a P/E ratio of 30.76, a P/E/G ratio of 2.13 and a beta of 0.25. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $37.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34.
In other Myriad Genetics news, insider Alexander Ford sold 3,031 shares of Myriad Genetics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 6.70% of the company’s stock.
MYGN has been the topic of a number of analyst reports. Barclays lowered their price objective on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 9th. Jefferies Group reaffirmed a “hold” rating and set a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Zacks Investment Research cut Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub raised Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Finally, Cowen reissued a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research note on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $28.10.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/06/commonwealth-equity-services-inc-acquires-new-position-in-myriad-genetics-inc-mygn.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.